Search
dasiglucagon (Zegalogue)
Indications:
- hypoglycemia in patients with diabetes mellitus
Dosage:
* 0.6 mL of 1 mg/mL autoinjector or pre-filled syringe for subcutaneous injection
Adverse effects:
- nausea/vomiting
- diarrhea
- headache
- injection site pain
Drug interactions:
- indomethacin: dasiglucagon may lose its ability to raise blood glucose or may produce hypoglycemia
- dasiglucagon may increase anticoagulant effect of warfarin
Mechanism of action:
- glucagon receptor agonist
General
endocrine agent
Database Correlations
PUBCHEM cid=126961379
References
- Alicea J
FDA Approves Dasiglucagon for Severe Hypoglycemia in Diabetic Patients.
HCP Live. March 23, 2021
https://www.hcplive.com/view/fda-approves-dasiglucagon-severe-hypoglycemia-diabetic-patients
- Li S, Hu Y, Tan X
Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.
Expert Opin Pharmacother 2020 Aug;21(11):1311-1318
PMID: 32267182
- ZEGALOGUE HIGHLIGHTS OF PRESCRIBING INFORMATION
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf